1
|
Schipper L, Samsom K, Snaebjornsson P, Battaglia T, Bosch L, Lalezari F, Priestley P, Shale C, van den Broek A, Jacobs N, Roepman P, van der Hoeven J, Steeghs N, Vollebergh M, Marchetti S, Cuppen E, Meijer G, Voest E, Monkhorst K. Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics. ESMO Open 2022; 7:100611. [PMID: 36463731 PMCID: PMC9808446 DOI: 10.1016/j.esmoop.2022.100611] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 09/08/2022] [Accepted: 09/12/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND In ∼3%-5% of patients with metastatic disease, tumor origin remains unknown despite modern imaging techniques and extensive pathology work-up. With long diagnostic delays and limited and ineffective therapy options, the clinical outcome of patients with cancer of unknown primary (CUP) remains poor. Large-scale genome sequencing studies have revealed that tumor types can be predicted based on distinct patterns of somatic variants and other genomic characteristics. Moreover, actionable genomic events are present in almost half of CUP patients. This study investigated the clinical value of whole genome sequencing (WGS) in terms of primary tumor identification and detection of actionable events, in the routine diagnostic work-up of CUP patients. PATIENTS AND METHODS A WGS-based tumor type 'cancer of unknown primary prediction algorithm' (CUPPA) was developed based on previously described principles and validated on a large pan-cancer WGS database of metastatic cancer patients (>4000 samples) and 254 independent patients, respectively. We assessed the clinical value of this prediction algorithm as part of routine WGS-based diagnostic work-up for 72 CUP patients. RESULTS CUPPA correctly predicted the primary tumor type in 78% of samples in the independent validation cohort (194/254 patients). High-confidence predictions (>95% precision) were obtained for 162/254 patients (64%). When integrated in the diagnostic work-up of CUP patients, CUPPA could identify a primary tumor type for 49/72 patients (68%). Most common diagnoses included non-small-cell lung (n = 7), gastroesophageal (n = 4), pancreatic (n = 4), and colorectal cancer (n = 3). Actionable events with matched therapy options in clinical trials were identified in 47% of patients. CONCLUSIONS Genome-based tumor type prediction can predict cancer diagnoses with high accuracy when integrated in the routine diagnostic work-up of patients with metastatic cancer. With identification of the primary tumor type in the majority of patients and detection of actionable events, WGS is a valuable diagnostic tool for patients with CUP.
Collapse
Affiliation(s)
- L.J. Schipper
- Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam,Oncode Institute, Utrecht, The Netherlands
| | - K.G. Samsom
- Department of Pathology, Netherlands Cancer Institute, Amsterdam
| | - P. Snaebjornsson
- Department of Pathology, Netherlands Cancer Institute, Amsterdam
| | - T. Battaglia
- Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam
| | - L.J.W. Bosch
- Department of Pathology, Netherlands Cancer Institute, Amsterdam
| | - F. Lalezari
- Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - P. Priestley
- Hartwig Medical Foundation Australia, Sydney, Australia
| | - C. Shale
- Hartwig Medical Foundation Australia, Sydney, Australia
| | | | - N. Jacobs
- Hartwig Medical Foundation, Amsterdam
| | | | | | - N. Steeghs
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam
| | - M.A. Vollebergh
- Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam
| | - S. Marchetti
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam
| | - E. Cuppen
- Oncode Institute, Utrecht, The Netherlands,Hartwig Medical Foundation, Amsterdam,Center for Molecular Medicine, UMC Utrecht, Utrecht
| | - G.A. Meijer
- Department of Pathology, Netherlands Cancer Institute, Amsterdam
| | - E.E. Voest
- Department of Molecular Oncology, Netherlands Cancer Institute, Amsterdam,Oncode Institute, Utrecht, The Netherlands,Department of Gastroenterology, Netherlands Cancer Institute, Amsterdam
| | - K. Monkhorst
- Department of Pathology, Netherlands Cancer Institute, Amsterdam,Correspondence to: Dr Kim Monkhorst, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Tel: +0205122948
| |
Collapse
|
2
|
Stoltenborg Granhøj J, Rohaan M, Holz Borch T, Presti M, Nijenhuis C, van Zon M, Jedema I, Nuijen B, Kessels R, Torres Acosta A, Lalezari F, van den Berg J, Donia M, Haanen J, Svane IM. 8P Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT) in patients with metastatic melanoma (MM). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
3
|
Haanen J, Rohaan M, Borch T, van den Berg J, Met Ö, Foppen MG, Granhøj JS, Nuijen B, Nijenhuis C, Beijnen J, Jedema I, van Zon M, Noringriis IM, Kessels R, Wilgenhof S, van Thienen H, Lalezari F, van Akkooi A, Donia M, Svane IM. LBA3 Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: Results from a multicenter, randomized phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.036] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Rohaan M, Gomez-Eerland R, van den Berg J, Geukes Foppen M, van Zon M, Raud B, Jedema I, Scheij S, de Boer R, Bakker N, van den Broek D, Pronk L, Grijpink-Ongering L, Sari A, Kessels R, van den Haak M, Mallo H, Karger M, van de Wiel B, Zuur C, Duinkerken C, Lalezari F, van Thienen J, Wilgenhof S, Blank C, Beijnen J, Nuijen B, Schumacher T, Haanen J. MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I/IIa clinical trial. Immuno-Oncology and Technology 2022; 15:100089. [PMID: 35865122 PMCID: PMC9293760 DOI: 10.1016/j.iotech.2022.100089] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- M.W. Rohaan
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R. Gomez-Eerland
- Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J.H. van den Berg
- Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M.H. Geukes Foppen
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M. van Zon
- Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - B. Raud
- Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - I. Jedema
- Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S. Scheij
- Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R. de Boer
- Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - N.A.M. Bakker
- Biotherapeutics Unit, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - D. van den Broek
- Department of Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - L.M. Pronk
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | | | - A. Sari
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R. Kessels
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M. van den Haak
- Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - H.A. Mallo
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - M. Karger
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - B.A. van de Wiel
- Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - C.L. Zuur
- Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - C.W. Duinkerken
- Department of Head and Neck Surgery, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - F. Lalezari
- Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J.V. van Thienen
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S. Wilgenhof
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - C.U. Blank
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - J.H. Beijnen
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - B. Nuijen
- Department of Pharmacy and Pharmacology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - T.N. Schumacher
- Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Oncode Institute, Utrecht, The Netherlands
| | - J.B.A.G. Haanen
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands
- Correspondence to: Prof. John B. A. G. Haanen, Department of Medical Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. Tel: 0031-205126979; Fax: 0031-205122572
| |
Collapse
|
5
|
Cooke S, De Ruysscher D, Reymen B, Lambrecht M, Fredberg Persson G, Faivre-Finn C, Dieleman E, Van Diessen J, Sikorska K, Lalezari F, Sonke J, Belderbos J. OA02.05 Local, Regional and Pulmonary Failures in the Randomised PET-Boost Trial for NSCLC Patients. J Thorac Oncol 2021. [DOI: 10.1016/j.jtho.2021.01.278] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
6
|
Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, Rozeman EA, Hartemink KJ, Swanton C, Haanen JBAG, Blank CU, Smit EF, Beets-Tan RGH, Aerts HJWL. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol 2020; 30:998-1004. [PMID: 30895304 PMCID: PMC6594459 DOI: 10.1093/annonc/mdz108] [Citation(s) in RCA: 305] [Impact Index Per Article: 76.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
INTRODUCTION Immunotherapy is regarded as one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds-urging the quest for predictive biomarkers. We hypothesize that artificial intelligence (AI) algorithms can automatically quantify radiographic characteristics that are related to and may therefore act as noninvasive radiomic biomarkers for immunotherapy response. PATIENTS AND METHODS In this study, we analyzed 1055 primary and metastatic lesions from 203 patients with advanced melanoma and non-small-cell lung cancer (NSCLC) undergoing anti-PD1 therapy. We carried out an AI-based characterization of each lesion on the pretreatment contrast-enhanced CT imaging data to develop and validate a noninvasive machine learning biomarker capable of distinguishing between immunotherapy responding and nonresponding. To define the biological basis of the radiographic biomarker, we carried out gene set enrichment analysis in an independent dataset of 262 NSCLC patients. RESULTS The biomarker reached significant performance on NSCLC lesions (up to 0.83 AUC, P < 0.001) and borderline significant for melanoma lymph nodes (0.64 AUC, P = 0.05). Combining these lesion-wide predictions on a patient level, immunotherapy response could be predicted with an AUC of up to 0.76 for both cancer types (P < 0.001), resulting in a 1-year survival difference of 24% (P = 0.02). We found highly significant associations with pathways involved in mitosis, indicating a relationship between increased proliferative potential and preferential response to immunotherapy. CONCLUSIONS These results indicate that radiographic characteristics of lesions on standard-of-care imaging may function as noninvasive biomarkers for response to immunotherapy, and may show utility for improved patient stratification in both neoadjuvant and palliative settings.
Collapse
Affiliation(s)
- S Trebeschi
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of Oncology and Developmental Biology, Maastricht, The Netherlands; Departments of Radiation Oncology; Radiology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | - S G Drago
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; Department of Radiology, Milano-Bicocca University, San Gerardo Hospital, Monza, Italy
| | - N J Birkbak
- The Francis Crick Institute, London; University College London, London, UK; Department of Molecular Medicine, Aarhus University, Aarhus, Denmark
| | - I Kurilova
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of Oncology and Developmental Biology, Maastricht, The Netherlands
| | - A M Cǎlin
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; Affidea Romania, Cluj-Napoca, Romania
| | - A Delli Pizzi
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; ITAB Institute for Advanced Biomedical Technologies, University G. d'Annunzio, Chieti, Italy
| | - F Lalezari
- Department of Radiology, Netherlands Cancer Institute, Amsterdam
| | - D M J Lambregts
- Department of Radiology, Netherlands Cancer Institute, Amsterdam
| | | | - C Parmar
- Departments of Radiation Oncology; Radiology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, USA
| | | | | | - C Swanton
- The Francis Crick Institute, London; University College London, London, UK
| | | | | | - E F Smit
- Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - R G H Beets-Tan
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; GROW School of Oncology and Developmental Biology, Maastricht, The Netherlands
| | - H J W L Aerts
- Department of Radiology, Netherlands Cancer Institute, Amsterdam; Departments of Radiation Oncology; Radiology, Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
| |
Collapse
|
7
|
Rohaan M, Gomez-Eerland R, Foppen MHG, van Zon M, de Boer R, Bakker N, Pronk L, Sari A, Mallo H, van de Wiel B, Lalezari F, Beijnen J, Nuijen B, van Tinteren H, van Thienen J, Blank C, Wilgenhof S, Schumacher T, van den Berg J, Haanen JBAG. Results of a phase I trial with MART-1 T cell receptor modified T cells in patients with metastatic melanoma. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz253.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
8
|
Burgers S, de Gooijer C, Cornelissen R, Aerts J, Biesma B, Heemst R, Youssef-El Soud M, Groen H, Staal-van den Brekel A, Bootsma G, Schijen JHEM, Baas P, Giovannetti E, de Vries J, Hogenboom F, de Wit D, Mahn- Schaefers M, Lalezari F, van de Noort V, Stigt J. Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.092] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
|
9
|
Rossi M, Fast M, Van de Lndt T, Nowee M, Belderbos J, Lalezari F, Sonke J. PO-0994 Registration accuracy of 4D-MRI in lung acquired on the MR-linac. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31414-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
10
|
Cobben D, Bainbridge H, Belderbos J, Cheung P, Dubec M, Gomez D, Gore E, Knowles E, Lalezari F, Oelfke U, Sonke J, Tijssen R, Van Es C, Van Herk M, Wetscherek A, McDonald F, Faivre-Finn C. EP-1346 A framework for systematic clinical evaluation of the MR-linac for treatment of lung cancer patients. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31766-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
11
|
Shiarli A, Brown S, Dubec M, Bainbridge H, Koh D, Lalezari F, Van Herk M, Wetscherek A, Knowles E, Faivre-Finn C, Mcdonald F. Gross tumour volume (GTV) delineation on magnetic resonance imaging (MRI), for stage III lung cancer: consensus recommendations needed to ensure contouring consistency. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30229-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
12
|
Cobben D, Bainbridge H, Belderbos J, Cheung P, Dubec M, Gomez D, Gore E, Knowles E, Lalezari F, Oelfke U, Sonke J, Tijssen R, Van Es C, Van Herk M, Wetscherek A, Mcdonald F, Faivre-Finn C. A framework for systematic clinical evaluation of technical innovations in lung cancer patients treated on the MR-linac (MRL). Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30184-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
13
|
van der Werf LR, Wassenaar E, de Niet A, Lalezari F, Braam HJ, van Ramshorst B, Nederend J, de Hingh IHJT, Kok NFM, Aalbers AGJ. The impact of radiological retroperitoneal lymphadenopathy on survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. Eur J Surg Oncol 2018; 45:376-382. [PMID: 30414704 DOI: 10.1016/j.ejso.2018.10.540] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/10/2018] [Accepted: 10/28/2018] [Indexed: 11/16/2022]
Abstract
OBJECTIVES To investigate the impact of retroperitoneal lymphadenopathy (RPLP) on pre-operative CT scan on overall survival (OS) and disease-free survival (DFS) after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) for peritoneal metastases (PM) of colorectal cancer. BACKGROUND In patients with PM enlarged retroperitoneal lymph nodes (RPLP) are usually considered extra-regional lymph node metastases and therefore these patients may be excluded from CRS-HIPEC. This is a clinical dilemma since it is often hard to obtain histology from these nodes. METHODS In this multicenter, retrospective study all consecutive patients with colorectal PM treated with CRS-HIPEC between 2004 and 2013 were included. The preoperative CT-scan was re-analyzed for the presence of RPLP based on the radiological appearance of enlarged lymph nodes. Outcomes were OS and DFS. Kaplan-Meier methods and Cox regression modeling were used to analyze the impact of RPLP on OS and DFS. RESULTS In 25 of 401 patients (6.1%) RPLP was observed on the preoperative CT-scan. Patient, tumor and surgical characteristics did not statistically significantly differ between groups with and without RPLP. After a median follow-up of 46 months, the one-, three- and five-year survival was 80%, 59%, 38% and 90%, 50%, 36% in the group with and without RPLP respectively. Median OS (47 vs. 35 months, logrank: p = 0.70) and median DFS (14 vs. 15 months, logrank: p = 0.81) did not statistically significantly differ between groups. In multivariable analysis, RPLP did not significantly influence survival. CONCLUSION Enlarged retroperitoneal lymph nodes on a pre-operative CT-scan should not automatically exclude patients from CRS-HIPEC.
Collapse
Affiliation(s)
- L R van der Werf
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
| | - E Wassenaar
- Department of Surgical Oncology, Antonius Hospital, Nieuwegein, the Netherlands
| | - A de Niet
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | - F Lalezari
- Department of Radiology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | - H J Braam
- Department of Surgical Oncology, Catharina Hospital, Eindhoven, the Netherlands
| | - B van Ramshorst
- Department of Surgical Oncology, Antonius Hospital, Nieuwegein, the Netherlands
| | - J Nederend
- Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands
| | - I H J T de Hingh
- Department of Surgical Oncology, Catharina Hospital, Eindhoven, the Netherlands
| | - N F M Kok
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands
| | - A G J Aalbers
- Department of Surgical Oncology, The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
| |
Collapse
|
14
|
Cobben D, Bainbridge H, Belderbos J, Cheung P, Dubec M, Gomez D, Gore E, Knowles E, Lalezari F, Oelfke U, Sonke J, Tijssen R, Van Es C, Van Herk M, Wetscherek A, Mcdonald F, Faivre-Finn C. P3.01-26 A Framework for Systematic Clinical Evaluation of Technical Innovations in Lung Cancer Patients Treated on the MR-Linac (MRL). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
15
|
Kraaijpoel N, Bleker S, van Es N, Mahé I, Muñoz A, Meyer G, Planquette B, Sanchez O, Bertoletti L, Accassat S, de Magalhaes E, Baars J, Rutten A, Lalezari F, Beyer-Westendorf J, Endig S, Marten S, Porreca E, Rutjes A, Russi I, Constans J, Boulon C, Kleinjan A, Beenen L, Iosub D, Piovella F, Couturaud F, Tromeur C, Biosca M, Assaf J, Helfer H, Pinson M, Lerede T, Falanga A, Lacroix P, Désormais I, Maraveyas A, Bozas G, Aggarwal A, Rickles F, Girard P, Caliandro R, Martinez del Prado P, de Prado Maneiro C, García Escobar I, Gonzàlez Santiago S, Schmidt J, Dublanchet N, Aquilanti S, Confrere E, Paleiron N, Grange C, Sevestre M, Ferrer Pérez A, Salgado Fernández M, Falvo N, Thaler J, Otten H, Carrier M, Bergmann J, Büller H, Di Nisio M. Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study. Thromb Res 2018. [DOI: 10.1016/j.thromres.2018.02.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
16
|
Meerveld-Eggink A, Rozeman E, Lalezari F, van Thienen J, Haanen J, Blank C. Short-term CTLA-4 blockade directly followed by PD-1 blockade in advanced melanoma patients: a single-center experience. Ann Oncol 2017; 28:862-867. [DOI: 10.1093/annonc/mdw692] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Indexed: 01/23/2023] Open
|
17
|
Rozeman E, Meerveld-Eggink A, Lalezari F, van Thienen J, Haanen J, Blank C. Single center experience on patients with advanced melanoma treated with short-term anti-CTLA4 directly followed by anti-PD-1. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw379.15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Saltzherr TP, Lalezari F, Gratama JW, Spronk PE. A case of abdominal tamponade. Neth J Med 2012; 70:139-142. [PMID: 22516579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Affiliation(s)
- T P Saltzherr
- Department of Surgery, Gelre Hospital, Apeldoorn, the Netherlands.
| | | | | | | |
Collapse
|
19
|
van den Broek T, Lalezari F, Brouwers HA, Beek FJ. Unilateral thymus displacement. JBR-BTR 2009; 92:174-175. [PMID: 19670585] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Affiliation(s)
- Th van den Broek
- Department of Neonatology, University Medical Centre Utrecht, Utrecht, The Netherlands
| | | | | | | |
Collapse
|